drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous chimeric antigen receptor T-cell therapy engineered to recognize a B-lineage surface antigen and kill antigen-positive cells, depleting autoreactive B-lineage cells to reduce autoantibody production in SLE.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered with a chimeric antigen receptor that recognizes a B-lineage surface antigen; upon antigen binding, CAR T cells become activated and cytotoxically eliminate antigen-positive B-lineage cells (e.g., autoreactive B cells/plasmablasts), thereby depleting autoantibody-producing cells and reducing pathogenic autoimmunity in SLE.
drug_name
ATHENA CAR-T (ET-901)
nct_id_drug_ref
NCT06373991